Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)

Stock Price: $38.22
+0 (0%)
Updated Dec 27, 2021 05:00 AM GMT+0000
Overview
Financials
Statistics
Profile
Chart
Market Cap 2.99B
Revenue 0
Gross Profit 0
Shares Out 78.13M
EPS (ttm)
PE Ratio 0.0000
Forward PE 0.0000
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Dec 27
Last Price $38.22
Previous Close $38.22
Change ($) 0
Change (%) 0%
Day's Open 38.22
Day's Range 38.21 - 38.24
Day's Volume 0
52 Week Range 0 - 38.24

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease.

Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities.

Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc.

Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.

News

Quick info

Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
CEO
Douglas Fambrough
Address
33 Hayden Avenue
Lexington
Massachusetts
02421
Phone
16176218097
Website
www.dicerna.com
Ticker Symbol
DRNA
Reporting Currency
USD